What To Look Out For At ESMO 2024

Attendees at this year's European Society for Medical Oncology meeting in Barcelona can look forward to a range of interesting datasets, from Phase III trials of established products in new settings to preliminary studies of novel products coming through the pipeline.

Sagrada Familia, Barcelona — Barcelona Is The Venue For ESMO 2024 • Source: Shutterstock

Among the presentations at the European Society for Medical Oncology meeting in Barcelona, Spain will be data for older immune checkpoint inhibitors from Merck & Co., Inc., AstraZeneca PLC and Bristol Myers Squibb Company in earlier lines of treatment, plus new results from the troubled TIGIT class. An array of early-stage results for innovative anticancers including drugs targeting claudin-6 and CDK2, and protein degraders will also be on show, at the conference which will run from 13-17 September.

The announcement last month of BMS’s long-awaited Phase III study on its combination anticancer product Opdualag in non-small-cell lung cancer (NSCLC) has given a strong hint as to where the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.